


Enhanced Discriminatory Receptors (EDR) - enhancing discriminatory power of T cells

A platform technology that uses the T cell receptor alpha and beta chains to produce a CD3-independent enhanced discriminatory receptor exhibiting high on-target potency with dramatically reduced off-target cross-reactivity.

Applications: TCR-T Cell Therapy



Features	Benefits
Uses existing candidate TCRs	Improves efficacy and reduces cross-reactivity (without modifying the TCR variable domains, i.e. no CDR changes required)
Modified signalling enables selective responses to high affinity on-target antigens	Reduced or abolished responses to lower-affinity off-target antigens (i.e. reduced cross-reactivity)
Surface expression is CD3-independent	No mispairing with endogenous TCRs
	High surface expression

Features

Benefits

Can be expressed in any cell (T cells, NK cells, macrophages, etc)

Patented and Available for

- Co-development
 - Consulting
 - Licensing
-

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.